Scopus
YÖKSİS Eşleşti
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
Indian Journal of Clinical Biochemistry · Ocak 2024
YÖKSİS Kayıtları
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
Indian Journal of Clinical Biochemistry · 2024 ESCI
PROFESÖR SEDAT ABUŞOĞLU →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY · 2024 EMBASE
PROFESÖR ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
Indian Journal of Clinical Biochemistry · 2024 ESCI
PROFESÖR ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
Indian Journal of Clinical Biochemistry · 2022 ESCI
PROFESÖR ALİ ÜNLÜ →
Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY · 2022 EBSCO, İndex Copernicus
PROFESÖR ALİ ÜNLÜ →
Makale Bilgileri
DergiIndian Journal of Clinical Biochemistry
Yayın TarihiOcak 2024
Cilt / Sayfa39 · 130-135
Scopus ID2-s2.0-85137510296
Özet
In this study, it was aimed to assess effects of subclinical hyperthyroidism (SH) on bone metabolism using osteoprotegerin (OPG), sclerostin, Dickkopf-1 (DKK1) and biochemical parameters. This cross-sectional prospective study included 40 patients with SH and 40 euthyroid controls. Serum OPG, sclerostin, DKK-1, type-1 procollagen, C-terminal polypeptide (CTx) and 24-hours urine N-terminal telopeptide (NTx) were measures using ELISA kit. Bone mineral density measurements were performed using dual energy X-ray absorptiometry (DEXA). Risk for 10-years hip and major fracture was estimated by Turkish version of FRAX. No significant difference was detected in age, gender, body mass index, smoking and menopause rates between SH and control groups. The risk for 10-years hip fracture and major osteoporotic fracture were estimated as 4.45% and 0.55% in SH group, respectively. The OPG levels were significantly lower in patients with SH than controls (P = 0.017). No significant difference was detected in other bone formation and degradation parameters. No significant correlation was detected between OPG level and risk for major osteoporotic fracture (P > 0.05); however, a negative correlation was detected between OPG level and risk for hip fracture (rho = 0.233; P = 0.038). Serum OPG is markedly affected in patients with SH. In addition, OPG seemed to be associated with osteoporotic fracture risk. Available data show that SH is significantly associated with risk for fracture; thus, it is important to assess risk for fracture in patients with SH.
Yazarlar (8)
1
Ayşe Elverdi Özbek
ORCID: 0000-0003-2677-9510
2
Huseyin Korkmaz
3
Mehmet Sözen
ORCID: 0000-0002-8428-1115
4
Suleyman Hilmi Ipekci
ORCID: 0000-0003-4410-2212
5
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
6
Cem Onur Kirac
7
Ali Ünlü
ORCID: 0000-0002-9991-3939
8
Levent Kebapcilar
Anahtar Kelimeler
Bone metabolism
DKK-1
Osteoprotegerin
Sclerostin
Subclinical hyperthyroidism
Kurumlar
İstanbul Atlas Üniversitesi
Istanbul Turkey
Kocaeli Üniversitesi
İzmit Turkey
Necip Fazil City Hospital
Kahramanmaras Turkey
Selçuk Tip Fakültesi
Konya Turkey
Selçuk Üniversitesi
Selçuklu Turkey